fenofibrate All Financial Data in US $ (mln)
Worldwide
 
Overview
 

Word Search (Top 10 - by date)

Interim Results Statement
SkyePharma (August 21, 2014)
Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
Salix Pharmaceuticals (August 19, 2014)
Salix Announces Important Topline Results for Microbiome, Culture & Susceptibility, and Key Secondary Efficacy Results for TARGET 3, Rifaximin IBS-D Repeat Treatment Study
Salix Pharmaceuticals (August 11, 2014)
FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain
Salix Pharmaceuticals (August 11, 2014)
Salix Pharmaceuticals Reports 2Q2014 Results
Salix Pharmaceuticals (August 07, 2014)
Cipher reports financial results for Q2 2014
Cipher Pharmaceuticals (July 30, 2014)
Salix and Pharming Announce FDA Approval of RUCONEST® for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Salix Pharmaceuticals (July 17, 2014)
FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain
Salix Pharmaceuticals (July 14, 2014)
Salix Pharmaceuticals to Combine with Cosmo Technologies to Form Salix Pharmaceuticals, plc
Salix Pharmaceuticals (July 08, 2014)
FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC
Salix Pharmaceuticals (June 12, 2014)

Displaying 10 out of a possible 498 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Summary Generic Name Information

Generic Name: fenofibrate
Therapeutic Subcategory:    Anti-hyperlipidaemics

Product Sales Summary

Annual Sales WW - Sales Growth per Year (%)
Rank1 Product Company 2010 2011 2011
Generic Name:2 fenofibrate 1,900 1,612 -15%
Note: Shaded Cells3

Evaluate - intelligence you can act on

Evaluate delivers market intelligence with standardized, transparent, integrated data that clients rely on.

Choose from a vast array of dynamic reports, customize, edit and download to PDF, Excel or create bespoke reports with expert client support.

Explore Content & Tools

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.  

Register Now